The United States has no shortage of scientific breakthroughs in industrial biotechnology, but turning them into domestic production, competitive manufacturing, and viable industries remains a challenge. Structural barriers – from fragmented infrastructure and uncertain demand to financing gaps and global competition – continue to slow deployment. This opening session sets the frame for the day by asking a central question: what will it take to move from isolated successes to building critical mass in American bioindustrial capacity?

The bioeconomy is often discussed in terms of future promise. Yet many of the technologies needed to transform manufacturing, strengthen supply chains, and enhance national competitiveness already exist. The question is no longer whether industrial biotechnology can deliver, but why deployment still lags. This keynote examines today's realities, emerging opportunities, and the choices that will determine whether the United States leads or follows in the next era of industrial production.

National strategies have established the importance of biotechnology and biomanufacturing, yet translating ambition into durable industrial capability continues to face structural constraints. This discussion explores what it will take to move from policy objectives to coordinated execution across government, industry, capital, and manufacturing, and how to close the gaps that limit long-term competitiveness in the U.S. bioindustrial ecosystem.

While bio-based supply chains still face challenges in feedstock reliability, logistics, and demand consistency, there are already clear examples where commercialization and reshoring are working. This session examines what enables those successes, why scaling remains difficult across much of the value chain, and what is required to create more consistent, reliable pathways from production to purchase.

Scaling bioindustrial technologies requires navigating the financial, policy, and operational decisions that ultimately determine whether innovations become viable businesses. This session brings together perspectives from investors and policy leaders to examine how those decisions are made and where they most often break down on the path to commercialization.

No single organization can build the bioeconomy alone. Success depends on connecting investors, manufacturers, technology developers, government, and customers into a system capable of moving opportunities forward. This fireside conversation explores why relationships – not just technologies – have become a strategic advantage, and how better coordination can shorten the path from innovation to industrial impact.

If public-private partnerships reduce risk, why is private capital still waiting? This panel examines where public-private partnerships have successfully advanced bioindustrial projects, where expectations have outpaced results, and what investors still need before committing larger pools of commercial capital.

The economics of bioindustrial manufacturing are shifting. Companies are beginning to challenge long-held assumptions about where production happens, how facilities are built, and what infrastructure is required. This session examines the emerging business models that could fundamentally reshape how industrial biotechnology scales.

The challenges facing the U.S. bioindustrial ecosystem are well understood, so the remaining question is who is prepared to act. This closing discussion moves beyond diagnosis to establish practical next steps and identify the partnerships, investments, and commitments to drive concrete action to build and sustain industrial critical mass.